Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making

Mira D Franken; Miriam Koopman; Martijn G H van Oijen

doi:10.1097/COC.0000000000000253

Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making

Mira D Franken, Miriam Koopman, Martijn G H van Oijen

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	214
Journal	American Journal of Clinical Oncology
Volume	39
Issue number	2
DOIs	https://doi.org/10.1097/COC.0000000000000253
Publication status	Published - Apr 2016

Keywords

Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Camptothecin
Cetuximab
Clinical Decision-Making
Colorectal Neoplasms
Cost-Benefit Analysis
Fluorouracil
Leucovorin
Quality-Adjusted Life Years
Letter

Access to Document

10.1097/COC.0000000000000253

Cite this

@article{1f6a029a461248e0b38894385d73791e,

title = "Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making",

keywords = "Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Cetuximab, Clinical Decision-Making, Colorectal Neoplasms, Cost-Benefit Analysis, Fluorouracil, Leucovorin, Quality-Adjusted Life Years, Letter",

author = "Franken, {Mira D} and Miriam Koopman and {van Oijen}, {Martijn G H}",

year = "2016",

month = apr,

doi = "10.1097/COC.0000000000000253",

language = "English",

volume = "39",

pages = "214",

journal = "American Journal of Clinical Oncology",

issn = "0277-3732",

publisher = "Lippincott Williams & Wilkins",

number = "2",

}

Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making. / Franken, Mira D; Koopman, Miriam; van Oijen, Martijn G H.
In: American Journal of Clinical Oncology, Vol. 39, No. 2, 04.2016, p. 214.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Cetuximab as First-line Treatment for Metastatic Colorectal Cancer

T2 - Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making

AU - Franken, Mira D

AU - Koopman, Miriam

AU - van Oijen, Martijn G H

PY - 2016/4

Y1 - 2016/4

KW - Antineoplastic Agents

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Camptothecin

KW - Cetuximab

KW - Clinical Decision-Making

KW - Colorectal Neoplasms

KW - Cost-Benefit Analysis

KW - Fluorouracil

KW - Leucovorin

KW - Quality-Adjusted Life Years

KW - Letter

U2 - 10.1097/COC.0000000000000253

DO - 10.1097/COC.0000000000000253

M3 - Comment/Letter to the editor

C2 - 26999056

SN - 0277-3732

VL - 39

SP - 214

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

IS - 2

ER -